Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Renal Cell 26Sarcoma 16Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 9Ovarian Neoplasms 8Breast Neoplasms 8Recurrence 6Neoplasms 5Melanoma 4Liposarcoma 4Leiomyosarcoma 4Glioblastoma 4Fallopian Tube Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Neuroendocrine Tumors 3Lung Neoplasms 3Kidney Neoplasms 3Hemangiosarcoma 3Gastrointestinal Stromal Tumors 3Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Sarcoma, Synovial 2Sarcoma, Alveolar Soft Part 2Rhabdomyosarcoma 2Pancreatic Neoplasms 2Osteosarcoma 2Gliosarcoma 2

Interventions

vandetanib 1ruxolitinib 1pazopanib 1fludarabine 1Vemurafenib 1Trastuzumab 1Sorafenib 1Imatinib Mesylate 1Ifosfamide 1Everolimus 1Etoposide 1Erlotinib Hydrochloride 1Dasatinib 1Cytarabine 1Crizotinib 1Carboplatin 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Relapsed Pediatric Solid Tumor × pazopanib × Clear all
NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Samsung Medical Center

Phase 2 Unknown
90 enrolled
Other solid neoplasm

Relapsed Pediatric Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡